Indian Journal of Nuclear Medicine
Home | About IJNM | Search | Current Issue | Past Issues | Instructions | Ahead of Print | Online submissionLogin 
Indian Journal of Nuclear Medicine
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 68 Print this page  Email this page Small font size Default font size Increase font size
COMMENTARY
Year : 2018  |  Volume : 33  |  Issue : 4  |  Page : 273-276

Impact of nuclear medicine and radiopharmaceuticals on health-care delivery: Advances, lessons, and need for an objective value-matrix


Adjunct Faculty, National Institute of Advanced Studies (NIAS), IISc Campus, Bangaluru, Karnataka, India; Division of Physical and Chemical Sciences, International Atomic Energy Agency (IAEA), Vienna, Austria

Correspondence Address:
Natesan Ramamoorthy
141 KBL Enclave Vijayanagara 4th Stage, 2nd Phase, Mysore - 570 032, Karnataka

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijnm.IJNM_56_18

Rights and Permissions

The nuclear medicine (NM) growth has gone through both evolutionary and revolutionary changes over decades, mostly attributable to the dynamic and responsive trends in the global development and deployment of radiopharmaceuticals (RPh), as well as the advent of superior technology imaging systems (single-photon emission computed tomography/computed tomography [CT], positron emission tomography [PET]/CT, PET/magnetic resonance) with quantification capability. There are naturally many crucial lessons learnt along the way of NM-RPh progress achieved. It is felt imperative for the NM-RPh community to have consensus-based list(s) of indications for NM, classified on the value-level basis, at NM gross-level and specific medical specialty-wise, and the corresponding RPh needed, to ensure harmonious communication with the referral medical fraternity and health-care policymakers. For this purpose, a “NM value-matrix” is proposed in terms of “NM utility grading” (unique value, significant value, useful value, and others) versus “patient volume” (i.e., large, medium, low, and rare cases), covering the established and emerging indications for NM procedure, and the corresponding RPh product(s) in use. A consensus-based NM Value-Matrix will portray in an unequivocal manner, the merits of NM-RPh options (also limitations, if any) for serving needy patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed220    
    Printed2    
    Emailed0    
    PDF Downloaded57    
    Comments [Add]    

Recommend this journal